Waystar CFO Steven Oreskovich sells $617,343 in stock

Published 14/03/2025, 21:34
Waystar CFO Steven Oreskovich sells $617,343 in stock

Steven M. Oreskovich, the Chief Financial Officer of Waystar Holding Corp. (NASDAQ:WAY), a $6.07 billion market cap company, recently sold shares valued at approximately $617,343. The transactions occurred on March 12, 2025, as per a filing with the Securities and Exchange Commission. According to InvestingPro data, the stock has delivered an impressive 70% return over the past year.

Oreskovich sold a total of 16,666 shares of Waystar common stock at prices ranging from $36.9969 to $38.0729. This sale was conducted under a pre-arranged trading plan designed to comply with Rule 10b5-1, which aims to shield insiders from accusations of insider trading. The company currently trades at a premium valuation with an EV/EBITDA multiple of 24.4x, while maintaining a GOOD financial health score based on InvestingPro’s comprehensive analysis.

In addition to the sales, Oreskovich exercised stock options to acquire 16,666 shares at a price of $4.14 each, amounting to a total value of $68,997. Following these transactions, Oreskovich holds 173,642 shares of Waystar, reflecting his continued stake in the company.

These activities underscore the dynamic nature of stock ownership among company executives and offer insight into the financial strategies of Waystar’s top leadership.

In other recent news, Waystar Holding has been in the spotlight with several significant developments. Goldman Sachs recently raised its price target for Waystar to $52, maintaining a Buy rating, after the company exceeded fourth-quarter 2024 revenue and profitability estimates by over $10 million and $5 million, respectively. This marks the third consecutive quarter of outperformance since Waystar’s IPO. Canaccord Genuity also increased its price target to $50, citing Waystar’s robust growth and successful client acquisition following a cybersecurity event at Change Healthcare (NASDAQ:CHNG). Truist Securities initiated coverage with a Buy rating and a $45 price target, highlighting Waystar’s strategic positioning in automated healthcare solutions.

In addition to analyst ratings, Waystar announced the launch of its Auth Accelerate solution, aimed at reducing healthcare authorization processing time by 70% and achieving an 85% auto-approval rate. This development is part of Waystar’s broader strategy to enhance healthcare payment processes. Moreover, Waystar has proposed a public offering of 18 million shares by certain investment funds, with the proceeds going to the selling stockholders rather than the company itself. These recent developments underscore Waystar’s ongoing efforts to innovate and expand within the healthcare payment industry.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.